ArticleAJOG global reports2026
Global, regional, and national burdens of liver disease due to hepatitis B in women of childbearing age, 1990 to 2021: an analysis of the Global Burden of Disease Study.
Article in AJOG global reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Women of childbearing age with hepatitis B are at risk for progression to life-threatening liver disease and vertical and horizontal transmission and have an increased risk for poor fetal health outcomes during pregnancy. Estimates of the burden of liver disease due to hepatitis B are scarce for women of childbearing age. Objective: This study aimed to use data from the Global Burden of Disease (GBD) Study to quantify the burden of liver disease due to hepatitis B in women of childbearing age at the global, regional, and national levels. Study Design: Annual counts of incident cases, prevalent cases, and deaths, and rates of incidence, prevalence, and mortality of liver disease due to hepatitis B in women of childbearing age (15-49 years) between 1990 and 2021 were collected from the GBD 2021. Percentage changes in counts of incident cases, prevalent cases, and deaths, and estimated annual percentage changes (EAPCs) in rates of incidence, prevalence, and mortality were calculated to quantify their temporal trends. Results: Globally, the absolute counts of liver disease due to hepatitis B in women of childbearing age decreased 3.45% from 18.45 million in 1990 to 17.82 million in 2021 for incident cases, by 1.08% from 74.50 million in 1990 to 73.35 million in 2021 for prevalent cases, and by 3.74% from 36.38 thousand in 1990 to 35.02 thousand in 2021 for deaths, respectively. The global rates of incidence, prevalence, and mortality of liver disease due to hepatitis B in women of childbearing age decreased by an average of 1.26% (95% confidence interval [CI]: 1.16%, 1.35%), 1.21% (95% CI: 1.12%, 1.31%), and 1.49% (95% CI: 1.42%, 1.55%) per year between 1990 and 2021, respectively. At the regional level, an increasing trend in the mortality of liver disease due to hepatitis B in women of childbearing age between 1990 and 2021 was observed in Australasia (EAPC=0.46; 95% CI: 0.23, 0.68), Eastern Europe (EAPC=3.39; 95% CI: 2.34, 4.45), and High-income North America (EAPC=0.77; 95% CI: 0.57, 0.97). At the national level, a significant increasing trend in the incidence rate, prevalence rate, and/or mortality rate of liver disease due to hepatitis B in women of childbearing age between 1990 and 2021 was observed in several countries, such as Denmark, the United Kingdom, and Ukraine. As of 2023, there were still 53 countries worldwide that have not yet introduced the hepatitis B birth dose vaccination in the national immunization program. These countries are mainly located in Sub-Saharan Africa, with a high incidence of liver disease due to hepatitis B in women of childbearing age and a high total fertility rate. Conclusion: The global rates of incidence, prevalence, and mortality of liver disease due to hepatitis B in women of childbearing age decreased between 1990 and 2021. An unfavorably increasing trend in the incidence rate, prevalence rate, and/or mortality rate of liver disease due to hepatitis B in women of childbearing age was observed in several countries, such as Denmark, the United Kingdom, and Ukraine. Thus, comprehensive strategies of screening, treatment, and/or vaccination services are important for reducing vertical transmission, horizontal transmission, and total disease burden of hepatitis B in women of childbearing age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.